Frei N F, Konté K, Duits L C, Klaver E, Ten Kate F J, Offerhaus G J, Meijer S L, Visser M, Seldenrijk C A, Schoon E J, Weusten B L A M, Schenk B E, Mallant-Hent R C, Bergman J J, Pouw R E
Department of Gastroenterology and Hepatology, Amsterdam UMC, location Vrije Universiteit, Amsterdam, The Netherlands.
Department of Pathology, University Medical Center, Utrecht, The Netherlands.
Dis Esophagus. 2021 Mar 8;34(3). doi: 10.1093/dote/doaa095.
The ReBus cohort is a matched nested case-control cohort of patients with nondysplastic (ND) Barrett's esophagus (BE) at baseline who progressed (progressors) or did not progress (nonprogressors) to high-grade dysplasia (HGD) or cancer. This cohort is constructed using the most stringent inclusion criteria to optimize explorative studies on biomarkers predicting malignant progression in NDBE. These explorative studies may benefit from expanding the number of cases and by incorporating samples that allow assessment of the biomarker over space (spatial variability) and over time (temporal variability). To (i) update the ReBus cohort by identifying new progressors and (ii) identify progressors and nonprogressors within the updated ReBus cohort containing spatial and temporal information. The ReBus cohort was updated by identifying Barrett's patients referred for endoscopic work-up of neoplasia at 4 tertiary referral centers. Progressors and nonprogressors with a multilevel (spatial) endoscopy and additional prior (temporal) endoscopies were identified to evaluate biomarkers over space and over time. The original ReBus cohort consisted of 165 progressors and 723 nonprogressors. We identified 65 new progressors meeting the same strict selection criteria, resulting in a total number of 230 progressors and 723 matched nonprogressors in the updated ReBus cohort. Within the updated cohort, 61 progressors and 107 nonprogressors (mean age 61 ± 10 years) with a spatial endoscopy (median level 3 [2-4]) were identified. 33/61 progressors and 50/107 nonprogressors had a median of 3 (2-4) additional temporal endoscopies. Our updated ReBus cohort consists of 230 progressors and 723 matched nonprogressors using the most strict selection criteria. In a subgroup of 168 Barrett's patients (the SpaTemp cohort), multiple levels have been sampled at baseline and during follow-up providing a unique platform to study spatial and temporal distribution of biomarkers in BE.
ReBus队列是一个匹配的巢式病例对照队列，其基线时为无发育异常（ND）的巴雷特食管（BE）患者，这些患者进展为高级别发育异常（HGD）或癌症（进展者）或未进展（非进展者）。该队列采用最严格的纳入标准构建，以优化对预测NDBE恶性进展的生物标志物的探索性研究。这些探索性研究可能受益于增加病例数量，并纳入能够评估生物标志物在空间（空间变异性）和时间（时间变异性）上变化的样本。目的是：（i）通过识别新的进展者来更新ReBus队列，以及（ii）在包含空间和时间信息的更新后的ReBus队列中识别进展者和非进展者。通过在4个三级转诊中心识别因肿瘤内镜检查而转诊的巴雷特患者来更新ReBus队列。识别具有多级（空间）内镜检查和额外既往（时间）内镜检查的进展者和非进展者，以评估生物标志物在空间和时间上的变化。原始的ReBus队列由165名进展者和723名非进展者组成。我们识别出65名符合相同严格选择标准的新进展者，更新后的ReBus队列中进展者总数为230名，匹配的非进展者为723名。在更新后的队列中，识别出61名进展者和107名非进展者（平均年龄61±10岁）进行了空间内镜检查（中位数水平为3 [2 - 4]）。61名进展者中的33名和107名非进展者中的50名额外进行了中位数为3（2 - 4）次的时间内镜检查。我们更新后的ReBus队列采用最严格的选择标准，由230名进展者和723名匹配的非进展者组成。在168名巴雷特患者的亚组（SpaTemp队列）中，在基线和随访期间对多个水平进行了采样，为研究BE中生物标志物的空间和时间分布提供了一个独特的平台。
